A Study About How Blood Cell Growth Patterns Relate to Heart Health After Treatment for Hodgkin Lymphoma

Launched by CHILDREN'S ONCOLOGY GROUP · Jan 20, 2023

Keywords

ClinConnect Summary

This clinical trial is studying how certain patterns of blood cell growth, known as clonal hematopoiesis, might affect heart health in patients who have been treated for Hodgkin lymphoma. Some patients who receive cancer treatment at a young age may face heart-related issues later on. By looking for these specific blood cell patterns, doctors hope to identify which patients are at higher risk for heart problems after their treatment. This knowledge can help them monitor these individuals more closely to catch any heart issues early and provide appropriate care.

To participate in this study, patients need to be at least 7 years old and have completed their treatment on a specific trial called AHOD1331. They also need to be able to have a cardiac MRI, a type of heart scan, without sedation. It's important that participants or their guardians give written consent to join the study. The trial is currently recruiting, and it aims to help improve heart health monitoring for young Hodgkin lymphoma survivors, so they can receive the best possible care after their cancer treatment.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patient must be \>= 7 years of age at the time of enrollment (age to perform an MRI without sedation).
• • Enrolled and completed therapy on AHOD1331.
• • Not known to have had a primary event (relapse/second malignancy/death). Note: Subjects enrolled and/or treated on AHOD1331 at another institution are eligible if they are now being followed at the current Children's Oncology Group (COG) institution.
• • Patient must have access to cardiac MRI at institution where receiving follow-up care and must be able to complete cardiac MRI without sedation.
• • All patients and/or their parents or legal guardians must sign a written informed consent.
• • All institutional, Food and Drug Administration (FDA), and National Cancer Institute (NCI) requirements for human studies must be met
• Exclusion Criteria:
• • Medical contraindication to undergoing a cardiac MRI.
• • Removed from AHOD1331 therapy prior to completing the AHOD1331 protocol specified treatment plan.
• • Received cancer therapy in addition to that of AHOD1331 (e.g., for disease progression or recurrence, or subsequent malignant neoplasm).
• • History of cardiovascular disease prior to enrollment on AHOD1331.